What does PHARMA BASE do?

PHARMA BASE is a logistics company in Genk. Public Limited, started on 10 October 1990, 3 establishments.

What is the address of PHARMA BASE?

The registered office of PHARMA BASE is located at Seinhuisstraat 7 box 1, 3600 Genk.

Is PHARMA BASE still active?

Yes. According to the CBE (29 October 2026) PHARMA BASE is active, legal situation “Normale toestand”, started on 10 October 1990.

Is PHARMA BASE registered on Peppol?

Yes, PHARMA BASE is registered on the Peppol network with ID 0208:0441943282.

What is the enterprise number of PHARMA BASE?

The enterprise number of PHARMA BASE is BE0441943282.

When was PHARMA BASE founded?

PHARMA BASE was founded on 10 October 1990.

Who are the directors of PHARMA BASE?

According to the 2024 annual accounts, the directors of PHARMA BASE are: Peeters Mathieu Management BV.

Is PHARMA BASE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 October 1990; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account; 3 establishments in the CBE.

How much profit did PHARMA BASE make in 2024?

PHARMA BASE posted a profit after taxes of € 178,876 in financial year 2024.

What is the revenue of PHARMA BASE?

In its most recent annual accounts (2024), PHARMA BASE reported revenue of € 75,243,950.

How much does an employee at PHARMA BASE earn?

The average wage cost per full-time employee at PHARMA BASE was € 45,300 in 2024: staff costs of € 1.3 million for 29 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA BASE have?

According to the 2024 annual accounts, PHARMA BASE has 29 full-time equivalents (FTE).

PHARMA BASE (Public Limited) - Genk - BE0441943282

Dossier PHARMA BASE, printed on 29 October 2026 from databakkes.be/en/0441943282/pharma-base. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

PHARMA BASE from Genk, company number BE0441943282, closed financial year 2024 with a result of € 178,876 after tax. For that financial year PHARMA BASE recorded revenue of € 75.2 million and equity of € 2.5 million. Compared with financial year 2023, the result moved from € 41,833 to € 178,876. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2025.

What it is worth Growing

€ 2.5 million

▲ 8% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 178,876

▲ € 137,042 vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 645,070

▼ 63% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 1.5 million.

People and assets in 2024

Full-time equivalents

▲ 6 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 2.9 million in 2024, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 1.3 million

▲ 24% vs 2023

€ 45,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 129,427

▲ 36% vs 2023

Of which on lease € 39,903.

Debts at end 2024

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2.7 million

▲ 26% vs 2023

€ 42,096 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 11.4 million

▲ 8% vs 2023

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 57 days on average.

Taxes and wages

€ 194,578

▼ 2% vs 2023

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	€ 56,162,582 Revenue 2021: € 56,162,582 First fiscal year in the series	€ 52,138,730 Revenue 2022: € 52,138,730 ▼ 7% vs 2021 (€ 56,162,582) Unfavourable step	€ 60,168,191 Revenue 2023: € 60,168,191 ▲ 15% vs 2022 (€ 52,138,730) Favourable step	€ 75,243,950 Revenue 2024: € 75,243,950 ▲ 25% vs 2023 (€ 60,168,191) Favourable step	▲ 25%
Profit after taxes	€ 485,519 Profit after taxes 2021: € 485,519 First fiscal year in the series	€ 147,347 Profit after taxes 2022: € 147,347 ▼ 70% vs 2021 (€ 485,519) Unfavourable step	€ 41,833 Profit after taxes 2023: € 41,833 ▼ 72% vs 2022 (€ 147,347) Unfavourable step	€ 178,876 Profit after taxes 2024: € 178,876 ▲ € 137,042 vs 2023 (€ 41,833) Favourable step	▲ € 137,042
Equity	€ 4,158,999 Equity 2021: € 4,158,999 First fiscal year in the series	€ 2,306,346 Equity 2022: € 2,306,346 ▼ 45% vs 2021 (€ 4,158,999) Unfavourable step	€ 2,348,180 Equity 2023: € 2,348,180 ▲ 2% vs 2022 (€ 2,306,346) Favourable step	€ 2,527,055 Equity 2024: € 2,527,055 ▲ 8% vs 2023 (€ 2,348,180) Favourable step	▲ 8%
Total debts	€ 13,361,969 Total debts 2021: € 13,361,969 First fiscal year in the series	€ 17,546,057 Total debts 2022: € 17,546,057 ▲ 31% vs 2021 (€ 13,361,969) Unfavourable step	€ 16,735,947 Total debts 2023: € 16,735,947 ▼ 5% vs 2022 (€ 17,546,057) Favourable step	€ 18,536,556 Total debts 2024: € 18,536,556 ▲ 11% vs 2023 (€ 16,735,947) Unfavourable step	▲ 11%
Cash	€ 1,990,313 Cash 2021: € 1,990,313 First fiscal year in the series	€ 1,238,038 Cash 2022: € 1,238,038 ▼ 38% vs 2021 (€ 1,990,313) Unfavourable step	€ 1,725,001 Cash 2023: € 1,725,001 ▲ 39% vs 2022 (€ 1,238,038) Favourable step	€ 645,070 Cash 2024: € 645,070 ▼ 63% vs 2023 (€ 1,725,001) Unfavourable step	▼ 63%
Retained profit	€ 3,158,999 Retained profit 2021: € 3,158,999 First fiscal year in the series	€ 1,306,346 Retained profit 2022: € 1,306,346 ▼ 59% vs 2021 (€ 3,158,999) Unfavourable step	€ 1,348,180 Retained profit 2023: € 1,348,180 ▲ 3% vs 2022 (€ 1,306,346) Favourable step	€ 1,527,055 Retained profit 2024: € 1,527,055 ▲ 13% vs 2023 (€ 1,348,180) Favourable step	▲ 13%
Dividend	€ 0 Dividend 2021: € 0 First fiscal year in the series	€ 2,000,000 Dividend 2022: € 2,000,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 2,000,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 2,261,031 Bank debt 2021: € 2,261,031 First fiscal year in the series	€ 1,577,109 Bank debt 2022: € 1,577,109 ▼ 30% vs 2021 (€ 2,261,031) Favourable step	€ 2,119,622 Bank debt 2023: € 2,119,622 ▲ 34% vs 2022 (€ 1,577,109) Unfavourable step	€ 2,675,046 Bank debt 2024: € 2,675,046 ▲ 26% vs 2023 (€ 2,119,622) Unfavourable step	▲ 26%
Balance sheet total	€ 17,520,968 Balance sheet total 2021: € 17,520,968 First fiscal year in the series	€ 19,852,404 Balance sheet total 2022: € 19,852,404 ▲ 13% vs 2021 (€ 17,520,968) Unchanged	€ 19,084,126 Balance sheet total 2023: € 19,084,126 ▼ 4% vs 2022 (€ 19,852,404) Unchanged	€ 21,063,611 Balance sheet total 2024: € 21,063,611 ▲ 10% vs 2023 (€ 19,084,126) Unchanged	▲ 10%
Employees (FTE)	17.3 Employees (FTE) 2021: 17.3 First fiscal year in the series	18.8 Employees (FTE) 2022: 18.8 ▲ 1.5 vs 2021 (17.3) Unchanged	23 Employees (FTE) 2023: 23 ▲ 4.2 vs 2022 (18.8) Unchanged	29 Employees (FTE) 2024: 29 ▲ 6 vs 2023 (23) Unchanged	▲ 6

Key figures of PHARMA BASE, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to PHARMA BASE?

What happened at PHARMA BASE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 23, 2025 New annual accounts for financial year 2024: profit of € 178,876 (▲ € 137,042 vs 2023). Source: NBB ↗
Jul 1, 2024 New establishment in Genk. KBO
Jul 1, 2024 New establishment in Genk. KBO
2022 Peeters Mathieu Management BV became a director. NBB
Sep 23, 2015 New establishment in Genk. KBO
Oct 10, 1990 Start of the company according to the CBE. KBO

In short

From € 485,519 profit in 2021 to € 178,876 profit in 2024.

Paid € 471,232 in corporate taxes since 2021.

Best year ever: 2021, with € 485,519 profit.

Paid out € 2 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

peeters mathieu management 100%

The stake of peeters mathieu management comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA BASE

Behind PHARMA BASE is Peeters Mathieu Management BV. The shares are held by peeters mathieu management (100%).

Directors

According to the 2024 annual accounts

Peeters Mathieu Management BV

Director · represented by Mathieu Peeters

Also active at: APOTHEEK PEETERS - PETIT, Pharma Force, PEETERS PHARMA

since 2022

Shareholders

peeters mathieu management

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Seinhuisstraat 7 box 1

3600 Genk

2.361.766.193

Seinhuisstraat 7 box 2

3600 Genk

Active since 1 July 2024

2.369.271.025

Seinhuisstraat 7 box 1-2

3600 Genk

Active since 1 July 2024

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

INBA

€ 35,142 gross margin · 2025

EM GROUP

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0441.943.282

VAT number

BE 0441.943.282

Registered office

Seinhuisstraat 7 bus 1, 3600 Genk

Names & denominations

PHARMA BASE

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

10 October 1990

Peppol

Active · Active since 24 Jun 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA BASE

Financials

What happened to PHARMA BASE?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions